Soleno Therapeutics (SLNO) “announced that Soleno’s Marketing Authorization Application seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) ...

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Soleno Therapeutics, Inc. has announced positive results from its clinical program for VYKAT™ XR (diazoxide choline) extended-release tablets, aimed at treating hyperphagia in individuals with ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product ...

Soleno Therapeutics, Inc. (SLNO) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. A solid ...

On Tuesday, Piper Sandler reiterated a positive stance on Soleno Therapeutics Inc. (NASDAQ: SLNO) shares, maintaining an Overweight rating and a $145.00 price target.Currently trading at $75.58 ...

The latest price target for Soleno Therapeutics (NASDAQ:SLNO) was reported by Guggenheim on May 8, 2025. The analyst firm set a price target for $97.00 expecting SLNO to rise to within 12 months ...

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company's first commercial product, VYKAT™ XR (diazoxide choline) ...